Peer-Review Record
Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer
Biomedicines 2022, 10(6), 1419; https://doi.org/10.3390/biomedicines10061419
by
Raquibul Hannan 1,*, Michael J. Dohopolski 1, Laurentiu M. Pop 1
, Samantha Mannala 1, Lori Watumull 2, Dana Mathews 2, Ang Gao 3, Aurelie Garant 1, Yull E. Arriaga 4, Isaac Bowman 4, Jin-Sung Chung 5,6, Jing Wang 1, Kiyoshi Ariizumi 5,6, Chul Ahn 3, Robert Timmerman 1 and Kevin Courtney 4
, Samantha Mannala 1, Lori Watumull 2, Dana Mathews 2, Ang Gao 3, Aurelie Garant 1, Yull E. Arriaga 4, Isaac Bowman 4, Jin-Sung Chung 5,6, Jing Wang 1, Kiyoshi Ariizumi 5,6, Chul Ahn 3, Robert Timmerman 1 and Kevin Courtney 4
Biomedicines 2022, 10(6), 1419; https://doi.org/10.3390/biomedicines10061419
Submission received: 21 May 2022
/
Accepted: 26 May 2022
/
Published: 15 June 2022
(This article belongs to the Section Cancer Biology and Oncology)
Round 1
Reviewer 1 Report
This paper is sufficiently improved now.
Reviewer 2 Report
The manuscript is acceptable for publication
Reviewer 3 Report
Authors improved the overall quality of te manuscript.
